NEW THERAPEUTIC APPROACH FOR TREATMENT AGE-RELATED MACULAR DEGENERATION (AMD)

V. Jakšiċ ,
V. Jakšiċ

Clinic for eye disease, Medical faculty Pristina , Kosovska Mitrovica , Kosovo*

L. Žorić ,
L. Žorić

Clinic for eye disease, Medical faculty Pristina , Kosovska Mitrovica , Kosovo*

M. Mirković ,
M. Mirković

Clinic for eye disease, Medical faculty Pristina , Kosovska Mitrovica , Kosovo*

D. Stamenković ,
D. Stamenković

Clinic for eye disease, Medical faculty Pristina , Kosovska Mitrovica , Kosovo*

D. Vukša ,
D. Vukša

Clinic for eye disease, Medical faculty Pristina , Kosovska Mitrovica , Kosovo*

N. Popović
N. Popović

Clinic for eye disease, Medical faculty Pristina , Kosovska Mitrovica , Kosovo*

Published: 01.01.2008.

Volume 36, Issue 1 (2008)

pp. 95-98;

https://doi.org/10.70949/pramed200801233J

Abstract

Exudative age-related macular degeneration is leading cause of irreversible vision loss in developed countries. Subfoveal localisation of choroidal neovascular membrane is the most difficult form for treatment. At the last three years, the new group of agens well-known as anti-VEGF agens was approved for treatment of exudative AMD. In that purpose, intravitreally administrated agens is recommended. Efficacy and safety of anti-VEGF agens were proved in short-time follow up period.

Keywords

References

1.
C.H. M, S. M, J.C. S, P K. Acute retinal pigment epithelial tear following intravitreal bevacizumab (Avastin) injection for occult choroidal neovascularization secondary to age-related macular degeneration. Br J Ophthalmol. 90:1207–8.
2.
E.S. G, A.P. A, E.T.Jr. C. VEGF Inhibition study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 351:2805–16.
3.
P.J. R, D.M. B, J.S. H. MARINA study group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 355:1419–31.
4.
D.M. B, P.K. K, M. M. ANCHOR study group. Ranibizumab versus verteporfirin for neovascular age-related macular degeneration. N Engl J Med. 355:1432–44.
5.
J. S, R.I. A, G. H. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin. Retina. 26:262–9.

Citation

Copyright

Article metrics

Google scholar: See link

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Most read articles

Indexed by